Hoffman S L, Rustama D, Dimpudus A J, Punjabi N H, Campbell J R, Oetomo H S, Marwoto H A, Harun S, Sukri N, Heizmann P
Lancet. 1985 Nov 9;2(8463):1039-40. doi: 10.1016/s0140-6736(85)90908-0.
2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera were available, and the isolate from this patient was sensitive to mefloquine in vitro. Only 2 of 41 infections studied at the same time were resistant in vivo to SP. There was no clinical advantage of MSP compared with SP, and limited observations suggest there may be a disadvantage.
在印度尼西亚伊里安查亚省查亚普拉，36例恶性疟原虫感染中有2例（RII和RIII）在体内对甲氟喹（M）和周效磺胺-乙胺嘧啶（SP）的联合用药产生耐药。在有血清样本的1例耐药患者中，证实了甲氟喹和乙胺嘧啶的预期吸收情况，并且该患者的分离株在体外对甲氟喹敏感。同时研究的41例感染中，只有2例在体内对SP耐药。与SP相比，MSP没有临床优势，有限的观察结果表明可能存在劣势。
